|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||12.82 - 14.00|
|52 Week Range||4.52 - 23.24|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported business and financial results as of and for the quarter ended September 30, 2019 and provided a corporate update.
DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that company manage
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from their actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements.
DermTech, Inc. , a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the presentation of new data on the Pigmented Lesion Assay at the Fall Clinical Dermatology Conference in Las Vegas, NV.
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its common stock will continue trading on The Nasdaq Capital Market under the symbol “DMTK.” On October 16, 2019, the Nasdaq Hearings Panel (the “Panel”) notified DermTech that it has granted the Company’s request for continued listing of its common stock on The Nasdaq Capital Market because the Company meets all of the requirements for initial listing. The Panel also determined to delist the Company’s warrants previously trading on The Nasdaq Capital Market under the ticker symbol “DMTKW” (the “Public Warrants”) due to the Company’s failure to demonstrate compliance with Nasdaq Listing Rule 5515(a)(4), which requires the Company to have a minimum of 400 round lot holders of its publicly traded warrants.
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a global leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its inclusion in Clinical Management Recommendations, “Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Process Assessment” published in the September issue of SKIN. A panel of dermatologists and dermatopathologists with expertise in pigmented lesions, melanoma, and gene expression technology evaluated commercially available gene expression tests to provide recommendations for use in specific clinical situations. The expert panel recommended use of the non-invasive PLA (Pigmented Lesion Assay), or 2-Gene Expression Profile test, in cases in which patients present with atypical lesions requiring additional assessment beyond visual inspection in order to inform the decision to surgically biopsy.
DermTech, Inc. , a global leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the issuance of patent, US 10,407,729, further expanding the company’s intellectual property and leadership position.